1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising

 
• By Alaric DeArment

The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.

Unity announced results from its Phase II study in wet AMD • Source: Shutterstock

The path ahead for UNITY Biotechnology, Inc.’s UBX1325 in patients with wet age-related macular degeneration (AMD) has become less straightforward as the company announced that its Phase II study did not show non-inferiority to Regeneron Pharmaceuticals, Inc.’s Eylea (aflibercept). Consequently, there is greater hope among analysts for Unity’s diabetic macular edema (DME) program, particularly the Phase II BEHOLD clinical trial of UBX1325, a program that has shown stronger data to date.

Unity announced results from Part A of the Phase II ENVISION trial in AMD on 27 March, saying that UBX1325 administered as a monotherapy did not achieve non-inferiority compared with Eylea through 24 weeks due, in part, to an unexpected 3.5-letter gain in the control arm

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.